





FIGURE 1

A



B




FIGURE 2




FIGURE 3




FIGURE 3 (contd.)





FIGURE 5





FIGURE 4




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 9 (contd.)




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15






FIGURE 16





% of GranToxiLux+ cells				
		Average	STDVE	
IgG1	25.1	27.8	26.45	1.909188
B07	78.4	76.2	77.3	1.555635
E07	68.6	68.7	68.65	0.070711
G04	55.6	58.4	57	1.979899
C08	50.7	36.6	43.65	9.970206

FIGURE 18




FIGURE 19




FIGURE 20




FIGURE 21

c)

% improvement in EC50	
No mAb	100%
D1.3 IgG1	109%
1252_P01_C08 IgG1	337%
1245_P02_G04 IgG	383%
1245_P01_E07 IgG	159%

D)

EC50s		
	$\gamma\delta$ T-cell	T:E ratio
No mAb	8729	0.11
D1.3 IgG1	8019	0.12
1252_P01_C08 IgG1	2594	0.39
1245_P02_G04 IgG	2278	0.44
1245_P01_E07 IgG	5485	0.18

FIGURE 21 (contd.)




FIGURE 22

i

	EC50s		
	$\gamma\delta$ T-cell	T:E ratio	% improvement
No mAb	4102	0.24	100%
D1.3 IgG1	3651	0.27	112%
D1.3 IgG LAGA	3640	0.27	113%
E07-LAGA	3229	0.31	127%
D1.3 FS1-67	2794	0.36	147%
Cetuximab	3246	0.31	126%
E07 FS1-67	1581	0.63	259%

j




FIGURE 22 (contd.)

A)

	EC50s		
	$\gamma\delta$ T-cell	T:E ratio	% improvement
RSV IgG	1988	1.99	100%
G04	2128	2.13	93%
E07	1775	1.78	112%
D1.3 VHVL	1143	1.14	174%
G04 VHVL	470	0.47	423%
E07 VHVL	828	0.83	240%

B)




FIGURE 23




FIG 24

Human Vδ1

Cyno Vδ1




FIG 25 cont.




FIG 25 cont.

E





FIG 25 cont.

F



G




FIG 25 cont.






FIG 25 cont.

J



K




FIG 26




FIG 26 cont.




FIG 26 cont.




FIG 26 cont.




FIG 27A
Binding to human Vd1




FIG 27B
Binding to human EGFR






FIG 28



B

EGFR

Overlay #4



Color

Population


viable cells (Unstained)

viable cells (EGFR)

C

VD1

Overlay #9



Color

Population

Event

% Total

viable cells (Unstained)

12771

67.24

viable cells (VD1)


12127

68.94

D

EGFR

Overlay #10



Color

Population

Event

% Total

viable cells (Unstained)

12771

67.24

viable cells (EGFR)

14031

68.75

FIG 28 cont.





FIG 29





FIG 29 cont.

D



E




FIG 30




FIG 31





FIG 31 cont.

B

IgG binding to BJ Fibroblasts



C

IgG binding to $\gamma\delta$ T-cells





FIG 31 cont.

D



E





FIG 31 cont.


F

CD107a expression on $\gamma\delta$ T-cells



G

CD107a expression on $\gamma\delta$ T-cells
in the presence of Fibroblasts



H

Fibroblast cytotoxicity




FIG 32

A





FIG 32 cont.

B

IgG binding to HeLa cells



C

IgG binding to $\gamma\delta$ T-cells





FIG 32 cont.

D



E






FIG 32 cont.

F



G



H




FIG 33

A





FIG 33 cont

B



C




FIG 33 cont

D






FIG 33 cont

E



F



G




FIG 34






FIG 34 cont.

B




C



D

FIG 34 cont.

IgG bound activated CD8 T-cells



IgG bound $\gamma\delta$ T-cells






FIG 34 cont.

E



F



G






FIG 35



B **FIG 35 cont.**



C





FIG 35 cont.

D



E





FIG 35 cont.

F



G






FIG 36

A



B

FIG 36 cont.



C




FIG 36 cont.

D






FIG 36 cont.


E



F



G






FIG 37






FIG 38

69/69

G



H



I




FIG 38 (cont)